These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32390066)

  • 1. Why it's Time to Abandon the ICER.
    Paulden M
    Pharmacoeconomics; 2020 Aug; 38(8):781-784. PubMed ID: 32390066
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation in medical information technology: why the numbers don't add up.
    Eisenstein EL; Ortiz M; Anstrom KJ; Crosslin DR; Lobach DF
    AMIA Annu Symp Proc; 2006; 2006():914. PubMed ID: 17238533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculating and Interpreting ICERs and Net Benefit.
    Paulden M
    Pharmacoeconomics; 2020 Aug; 38(8):785-807. PubMed ID: 32390067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
    Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
    [No Abstract]   [Full Text] [Related]  

  • 6. 5 ways to use medical technology assessments to reduce costs.
    Niederhausen J
    Healthc Financ Manage; 2014 Aug; 68(8):32. PubMed ID: 25145028
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
    Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
    Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography.
    Pertile P
    Int J Health Care Finance Econ; 2009 Sep; 9(3):317-32. PubMed ID: 19152067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for reporting health economic evaluation studies.
    Silva END; Silva MT; Augustovski F; Husereau D; Pereira MG
    Epidemiol Serv Saude; 2017; 26(4):895-898. PubMed ID: 29211152
    [No Abstract]   [Full Text] [Related]  

  • 11. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource modelling: the missing piece of the HTA jigsaw?
    Thokala P; Dixon S; Jahn B
    Pharmacoeconomics; 2015 Mar; 33(3):193-203. PubMed ID: 25411095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. It's time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies.
    Shavit O; Leshno M; Goldberger A; Shmueli A; Hoffman A
    Pharmacoeconomics; 2007; 25(11):903-11. PubMed ID: 17960950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transparency of economic evaluations of health technologies.
    Rovira J
    Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013
    [No Abstract]   [Full Text] [Related]  

  • 16. NICE, social values, and balancing objectivity and equity.
    Hill SR; Olson LG
    Pharmacoeconomics; 2014 Nov; 32(11):1039-41. PubMed ID: 25249201
    [No Abstract]   [Full Text] [Related]  

  • 17. Objectivity and equity: clarity required. A response to Hill and Olson.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Dec; 32(12):1249-50. PubMed ID: 25412736
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation approaches for new technology.
    Papatheofanis FJ
    IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
    [No Abstract]   [Full Text] [Related]  

  • 19. Striking a balance on new technology. Cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation?
    Philipson TJ; Jena AB
    AHIP Cover; 2006; 47(5):29, 31, 33. PubMed ID: 17007325
    [No Abstract]   [Full Text] [Related]  

  • 20. Introducing new health interventions.
    Gabbay J; Walley T
    BMJ; 2006 Jan; 332(7533):64-5. PubMed ID: 16410559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.